News for Edgewise Therapeutics, Inc. (EWTX)

Summary Edgewise Therapeutics Inc (EWTX), a prominent biopharmaceutical company specializing in muscle disease treatments, announced on June 3, 2025, that its m

Edgewise Therapeutics faces challenges with DMD/BMD programs, upcoming trial data concerns, and competitive risks.

Edgewise Therapeutics (EWTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PR NewswireBOULDER, Colo., May 14, 2025 BOULDER, Colo., May 14, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease

The mean of analysts' price targets for Edgewise Therapeutics (EWTX) points to a 174.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Edgewise Therapeutics (EWTX) is scheduled to present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025. The presentation will be a

Edgewise Therapeutics Inc's innovative approach to rare muscle disorders positions it as a potential leader in the biopharmaceutical industry.Despite being in

We recently published a list of Top 11 Small Cap Stocks to Buy with Biggest Upside Potential. In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against other top small cap stocks to buy with biggest upside potential. On April 24, Jill Carey Hall, BofA Securities head […]

We recently published a list of Top 11 Small Cap Stocks to Buy with Biggest Upside Potential. In this article, we are going to take a look at where Edgewise Therapeutics, Inc.

Edgewise Therapeutics (EWTX) experienced a notable uptick in its stock price, climbing 1.38% to $16.91. This movement comes in response to an analyst's initiati

Transaction Overview On April 24, 2025, Orbimed Advisors LLC executed a strategic transaction involving Passage Bio Inc (NASDAQ: PASG). The firm reduced its hol

Key Takeaways: Guggenheim initiates coverage on Edgewise Therapeutics with a buy rating, citing a robust drug pipeline. The firm has set an ambitious pri

U.S. stock futures were lower this morning, with the Nasdaq futures falling around 1% on Monday. Shares of Tesla, Inc. TSLA fell sharply in today's pre-market ...

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a...

We recently published a list of 20 Stocks Insiders Bought in April After Trump’s Tariff Rollout. In this article, we are going to take a look at where Edgewise Therapeutics, Inc.

We recently published a list of 20 Stocks Insiders Bought in April After Trump’s Tariff Rollout. In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against other stocks that insiders bought in April after Trump’s tariff rollout. President Donald Trump called April 2 a “Liberation Day” after […]

We recently published a list of 10 Unstoppable Stocks That Could Double Your Money. In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against other unstoppable stocks that could double your money. Generating significant returns and multiplying their money in the stock market remains a primary goal […]

Edgewise Therapeutics (EWTX, Financials) was downgraded by Scotiabank after disclosing safety concerns in a mid-stage clinical trial for its investigational hea

Discover growth opportunities with Edgewise Therapeutics, Inc. in the hypertrophic cardiomyopathy market. Click for my EWTX stock update.